Resonandina Holanda

Company profile

Resonandina: A Pioneer in Sustainable Medical Leasing

Resonandina is a profitable, sustainable medical lease scale-up founded in the Netherlands, dedicated to making diagnostics accessible to everyone. By offering pay-per-use leasing of high-quality, capital-intensive diagnostic equipment (MRI, PET/CT, and more), Resonandina bridges the gap for hospitals that lack the resources or expertise to acquire such solutions. This model not only provides access to advanced equipment but also ensures economic and social returns in all activities.

Problem: Hospitals often lack resources or knowledge for capital intensive medical equipment.

Solution: Resonandina developed an innovative all-inclusive pay-per-use medical lease model that makes diagnostics accessible for everyone.

Capital-intensive equipment becomes affordable for hospitals because a small amount has to be paid each month instead of a large lump sum. The key differentiator of Resonandina is the focus on a ‘simple’ and client oriented “B2B” business model based on “Pay-per-Use” lease with a “all-inclusive” package. The service includes project design, investment, installation, training, full maintenance, and extended life cycle (with upgrades, reuse, and recycling). The hospital has all the medical related responsibilities like patient logistics, quality management, liability and (insurance) invoicing.

Resonandina ensures that these hospitals can deploy advanced equipment so that diagnostics become affordable and available to all. This results in healthier people and fewer travel movements.

Resonandina started the services in 2015 in Bolivia with a step-by-step expansion to other Latin American countries. Submarkets are: “doctor owned” medium size hospitals, larger professionally managed hospitals, and Public Healthcare Services.

Having a unique concept of “use it, don’t own it” Resonandina is market leader with focus on the “niche” of high-end medical diagnostic imaging. With a strong partner in GE Healthcare. Fundamental is the Recurring Revenue model with long term (8+ YR) contracts. With 14 units producing, 5+ in installation, and a pipeline (2025) for 25+ projects there is a great potential.

Resonandina aims at 70+ projects with €25 million ARR by 2030. The market size is estimated at 100,000 projects per 2030. Resonandina successfully created a recognized market position, defined the service and operational execution, managed to create ARR and profitability, has proven the concept, prepared footprints in the addressable markets and is ready for the leap ahead. In difference with the previous campaign communications, we decided to focus primarily on our ‘home-market’ with a more conservative projection of 70 instead of 500 projects in Latin America and Caribbean and expand in a later stage to other continents.

Developments since the last funding round with Invesdor

You know this company already because of the last funding round? Find out more about what has happened since then.

Company Info 

Products and services

Resonandina developed an innovative sustainable medical lease model that makes diagnostics accessible for everyone.

High-Quality Equipment

Aligning with technological medical developments, hospitals need equipment that meets high standards—certified and guaranteed by manufacturers. Main areas of equipment include:

• General Medicine, Traumatology, Orthopedics, Neurosurgery, Oncology (MRI, CT).
• Cardiology, Neurology (Angio), Radiotherapy (Linear Accelerator, Brachytherapy).
• Nuclear Medicine (Cyclotron, PET/CT).
• Robotics (Operation Theatre).

Full-Service Maintenance

Resonandina provides comprehensive, long-term maintenance without hidden fees. This includes:

• Project design and site planning.
• Delivery and installation.
• Training, monitoring, and maintenance.
• Upgrades and parts replacement to extend the equipment’s lifespan.

All services are executed by the OEM or certified third parties, ensuring reliability and optimal performance.

Long-Term Commitment

Through partnerships, hospitals can focus on patient diagnostics while Resonandina manages the equipment’s technical functionality and output optimization. This results in reliable, efficient operations and improved healthcare delivery.

Upgrade & Reuse

At the end of a contract, equipment is upgraded to meet evolving expectations. Parts are reused or recycled, enhancing sustainability and extending the equipment’s life cycle. For example, Resonandina’s MRI program extends the life span of an MRI from 90,000 scans to 135,000 scans.

How does it work?

This model allows hospitals to offer advanced diagnostic services without the financial burden of purchasing equipment outright. By preserving operational liquidity and providing flexibility in financial planning, Resonandina ensures healthcare providers can focus on patient care. The pay-per-use system, combined with volume discounts, incentivizes hospitals to maximize equipment usage, improving both efficiency and profitability. Resonandina offers a practical, transparent, and affordable financial solution for hospitals.

By integrating flexible leasing solutions with comprehensive services, Resonandina ensures that hospitals can focus on patient care while improving operational efficiency and profitability.

Business model

Resonandina employs a unique business model that revolutionizes access to capital-intensive medical equipment by shifting the financial burden from upfront investment (CAPEX) to operational expenses (OPEX). This approach ensures that hospitals can acquire and operate state-of-the-art diagnostic equipment without compromising their financial stability.

Financial Model

Resonandina’s financial model is built on a pay-per-use system, where hospitals pay a fee for each diagnostic scan performed. This structure aligns costs directly with usage, making the service both scalable and affordable. Volume discounts incentivize hospitals to increase equipment utilization by lowering the cost per scan as usage grows. Additionally, hospitals commit to a minimum number of scans each month, guaranteeing a stable revenue stream for Resonandina while promoting optimal equipment use.

Hospitals generate income from each scan by billing patients or insurers based on local tariffs. For example, they might pay Resonandina $50 per scan for the first 350 scans and a reduced rate for higher volumes. This tiered pricing model supports hospital profitability while maintaining Resonandina’s recurring revenue. On average, Resonandina earns $300,000 to $350,000 annually in recurring revenue for every $1 million invested in medical equipment.

Contractual and Client Details

Resonandina enters into long-term lease agreements that typically last between 6 and 15 years, aligning with the economic life cycle of the equipment. The primary market includes medium-sized, doctor-owned hospitals and larger professionally managed facilities in underserved regions with over 250,000 inhabitants. These hospitals often face capital constraints, making Resonandina’s flexible leasing solutions an ideal fit. For larger institutions, the model provides financial flexibility, allowing them to invest in other critical areas while keeping their balance sheets free from heavy equipment assets.

Comprehensive Service Offering

Resonandina’s service package is designed to provide end-to-end support for hospitals, ensuring the smooth operation of leased equipment:

• Resonandina handles equipment acquisition and oversees delivery, installation, and site planning to ensure operational readiness.
• Full-service maintenance is included, covering parts replacement and technological upgrades to extend equipment lifespans.
• Training and support are provided to hospital staff to ensure efficient and effective use of the equipment.

Partnerships and Operational Support

Resonandina collaborates with leading original equipment manufacturers (OEMs) like GE Healthcare and certified local service providers. These partnerships guarantee high-quality installations, reliable maintenance, and optimal equipment performance throughout the contract duration.

Sustainability Focus

At the core of Resonandina’s model is a commitment to sustainability. Equipment is upgraded or recycled at the end of each contract, minimizing waste and reducing environmental impact. By extending the lifespan of diagnostic equipment, Resonandina supports responsible consumption and promotes sustainable practices in alignment with SDG 12.

Unique Selling Propositions (USPs)

Resonandina offers distinct advantages for both clients and investors:

• For Clients:
  • Affordable pay-per-use solutions under OPEX.
  • Comprehensive service packages, including financing, installation, training, and maintenance.
  • Proven expertise in local markets, supported by partnerships with top-tier OEMs.
• For Investors:
  • A solid 10-year track record in Latin America.
  • A history of debt-financed growth with strong returns.
  • A profitable scale-up led by an experienced team with operational, financial, and medical expertise.

Vision and Mission

• Vision: To create a better future through equitable access to diagnostic care and subsequent medical treatment for everyone.
• Mission: To make diagnostics accessible to everyone through innovative pay-per-use leasing models.

Market

Global Opportunity in Diagnostic Imaging

The global diagnostic imaging market offers substantial growth potential. Resonandina’s sustainable medical lease model addresses key challenges in this space.

Approximately 115,307 MRI and CT scanners are installed globally, with a 15-year lifespan leading to 7,500 units replaced annually. Additionally, rapid market growth - especially in Latin America (>10% annually) - adds approximately 6,000 new units each year, resulting in an annual market opportunity of 13,500 units.

Resonandina focuses on Latin America and the Caribbean, a region representing 9% of the global market. This area has an annual demand for 1,215 units. By 2030, the maximum potential is to reach an installed base of 247 units in this region, equating to 35 new units annually and capturing 3% of the market growth. However, Resonandina conservatively estimates a 1% market share, equivalent to 10 new installations per year, reaching a total installed base of 70+ units by 2030.

Competitive Landscape

Unlike traditional sales and financing models offered by OEMs like Siemens, Philips, and GE Healthcare, Resonandina provides a comprehensive pay-per-use solution with full-service support. This unique approach targets underserved markets, particularly in Latin America, where approximately 20% of hospitals cannot access capital-intensive equipment through conventional means. Resonandina stands out by addressing these needs with tailored leasing solutions for high-end medical imaging equipment.

Entry Barriers

Entering the diagnostic imaging market poses significant challenges. High capital requirements make it difficult for new competitors to acquire and maintain advanced medical equipment. Building partnerships with OEMs and local service providers is essential to ensure reliable operations, further adding to the complexity of market entry.

Establishing trust and a strong reputation takes years of consistent service delivery through long-term contracts. Moreover, creating an international corporate structure and developing efficient sales channels demand substantial resources and expertise.

Resonandina has overcome these barriers through its well-established network, proven business model, and first-mover advantage. By securing partnerships, developing a robust operational framework, and consistently delivering value, Resonandina has positioned itself as a trusted leader in sustainable diagnostic solutions, ensuring long-term growth and impact.

Management

Distribution of company shares

QMED BV is a private holding company controlled by founder Floriaan van Bemmelen.

Company structure

You are investing in Resonandina Holanda BV which lends money to its 7 100% operational subsidiaries. All these subsidiaries are 100% guarantor to this bond. The subsidiaries have to repay the loan(s) to the holding. Both the holding and the subsidiaries can be addressed to repay the Invesdor loan.

Developments at Resonandina since the last crowdfunding 

In 2024, we successfully raised €2.5 million Invesdor funding rounds as well as nearly €4.5 million from private investors and a local bank in Dominican Republic.

Here are the key achievements:

1. Installations: We completed installations for 7 projects across several countries: three in Colombia, one in Ecuador (all funded by Invesdor), one in St. Lucia, one in Grenada and one in Dominican Republic.
2. Revenue: Resonandina projects to achieve a total of €6.3 million revenue for 2025 of which €5.2 million is recurring revenue. A rise of €1.9 million compared to 2024 due to the extra installations in 2024. In 2024 the ARR was €3.5 million with a additional sale of €0.7 million. In 2025, it is anticipated to close a significant sales project again that will have a substantial impact on our revenue.
3. Profit: Since becoming profitable in 2021,we closed at €464,000 in 2024, expecting to grow to €1 million in 2025. The EBITDA made a significant rise from around €1 million in 2023 to €1.7 million in 2024. Resonandina reinvests profits.
4. Impact: We significantly contributed to SDG3 (Good Health and Well-being) in 2024, augmenting the diagnostic access for an estimated 3.5+ million people with the completed installations underway. and aiming at 5+ million in 2025 when all projects are full blown in production.
5. Expansion: We expanded our footprint by signing contracts and planning future installations. Projects funded by Invesdor set for 2025 include nuclear medicine project (PET/CT) and an MRI in Peru. Furthermore, already 9 additional projects are confirmed for 2025.
6. Management: We contracted two high-end professionals. Antonio Pimentel as COO and Luis de Valle as CFO giving more strength leading the company. In operations also a project manager joined, given the many installations in process. In the financial part we partner with PwC (Colombia) and the auditor BAAT (The Netherlands) to improve the administrative processes and internal reporting.

Use of funds

Resonandina’s current financing round is focused on accelerating installations and creating quicker impacts. The funds will be used as working capital to reduce delivery times for MRI installations, enabling faster patient access to diagnostic services and earlier revenue generation. By securing pre-financing for projects, Resonandina can cut MRI delivery times in half, ensuring quicker returns and enhanced impact.

This financing round differs from previous ones, as the company is not offering collateral for the bond. The reason for this approach lies in Resonandina’s growing working capital needs. In earlier rounds, financing parties covered up to 90% of the costs for MRI units, including hardware. However, significant additional costs—such as transportation, materials, taxes, transaction fees, and acquisition expenses—had to be pre-financed by the company. These upfront expenses created challenges and delayed installations.

With the funds raised in this round, Resonandina aims to reduce the average time to installation by 50%. This acceleration minimizes uncertainty, improves operational efficiency, and boosts profitability, making it possible to achieve quicker returns while maintaining high-impact outcomes. Through a strategic partnership with local banks, Resonandina covers the remaining investment needs, maximizing the efficiency of funds raised during this campaign. This approach guarantees a high return on investment while accelerating installations and improving access to essential diagnostics.

Investment related documents

Log in for more information.

There are currently no updates available.

This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.